Treatment of rheumatoid arthritis in the USA

Premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate

James Robert O'Dell, Stanley B. Cohen, J. Carter Thorne, Joel Kremer

Research output: Contribution to journalArticle

Abstract

Purpose: The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA. Patients and methods: This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort). Results: A biologic was initiated before MTX for 27% of the 2009 cohort and 36% of the 2012 cohort. Concomitant use of MTX and a biologic declined from 74.1% (2009 cohort) to 45.4% (2012 cohort). Conclusion: MTX is underused in the treatment of RA in the USA.

Original languageEnglish (US)
Pages (from-to)97-101
Number of pages5
JournalOpen Access Rheumatology: Research and Reviews
Volume10
DOIs
StatePublished - Jan 1 2018

Fingerprint

Methotrexate
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Insurance Claim Review
Therapeutics

Keywords

  • Biologic
  • Claims
  • Methotrexate
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Rheumatology

Cite this

Treatment of rheumatoid arthritis in the USA : Premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate. / O'Dell, James Robert; Cohen, Stanley B.; Carter Thorne, J.; Kremer, Joel.

In: Open Access Rheumatology: Research and Reviews, Vol. 10, 01.01.2018, p. 97-101.

Research output: Contribution to journalArticle

@article{774421c81dd649d2ab3dd9e9eae2b63f,
title = "Treatment of rheumatoid arthritis in the USA: Premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate",
abstract = "Purpose: The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA. Patients and methods: This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort). Results: A biologic was initiated before MTX for 27{\%} of the 2009 cohort and 36{\%} of the 2012 cohort. Concomitant use of MTX and a biologic declined from 74.1{\%} (2009 cohort) to 45.4{\%} (2012 cohort). Conclusion: MTX is underused in the treatment of RA in the USA.",
keywords = "Biologic, Claims, Methotrexate, Tumor necrosis factor",
author = "O'Dell, {James Robert} and Cohen, {Stanley B.} and {Carter Thorne}, J. and Joel Kremer",
year = "2018",
month = "1",
day = "1",
doi = "10.2147/OARRR.S169152",
language = "English (US)",
volume = "10",
pages = "97--101",
journal = "Open Access Rheumatology: Research and Reviews",
issn = "1179-156X",
publisher = "Dove Medical Press Limited",

}

TY - JOUR

T1 - Treatment of rheumatoid arthritis in the USA

T2 - Premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate

AU - O'Dell, James Robert

AU - Cohen, Stanley B.

AU - Carter Thorne, J.

AU - Kremer, Joel

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA. Patients and methods: This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort). Results: A biologic was initiated before MTX for 27% of the 2009 cohort and 36% of the 2012 cohort. Concomitant use of MTX and a biologic declined from 74.1% (2009 cohort) to 45.4% (2012 cohort). Conclusion: MTX is underused in the treatment of RA in the USA.

AB - Purpose: The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA. Patients and methods: This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort). Results: A biologic was initiated before MTX for 27% of the 2009 cohort and 36% of the 2012 cohort. Concomitant use of MTX and a biologic declined from 74.1% (2009 cohort) to 45.4% (2012 cohort). Conclusion: MTX is underused in the treatment of RA in the USA.

KW - Biologic

KW - Claims

KW - Methotrexate

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=85064749103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064749103&partnerID=8YFLogxK

U2 - 10.2147/OARRR.S169152

DO - 10.2147/OARRR.S169152

M3 - Article

VL - 10

SP - 97

EP - 101

JO - Open Access Rheumatology: Research and Reviews

JF - Open Access Rheumatology: Research and Reviews

SN - 1179-156X

ER -